Heribert Arnhof

发表

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

P. Ettmayer, S. Carotta, M. Kerenyi, 2020, Molecular Cancer Therapeutics.

Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3

Julian E. Fuchs, O. Fedorov, C. Arrowsmith, 2019, Nature Chemical Biology.

Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor

A. Waterson, D. Rudolph, M. Gmachl, 2022, Journal of medicinal chemistry.

Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.

Markus J. Bauer, P. Ettmayer, D. Rudolph, 2016, Journal of medicinal chemistry.

Detailed structure-activity relationship of indolecarboxamides as H4 receptor ligands.

R. Smits, I. D. de Esch, O. Zuiderveld, 2012, European journal of medicinal chemistry.

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design

William Farnaby, Peter Greb, Michael Galant, 2019, Nature Chemical Biology.

Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis.

P. Ettmayer, W. Sommergruber, M. Pearson, 2019, Journal of medicinal chemistry.

BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition.

P. Ettmayer, M. Pearson, T. Heffernan, 2020, Cancer discovery.

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

Stefan Fischer, G. Adolf, N. Kraut, 2017, Molecular Cancer Therapeutics.

Bispyrimidines as potent histamine H(4) receptor ligands: delineation of structure-activity relationships and detailed H(4) receptor binding mode.

I. D. de Esch, O. Zuiderveld, E. Haaksma, 2013, Journal of medicinal chemistry.

Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.

M. Koegl, P. Ettmayer, M. Pearson, 2019, Journal of medicinal chemistry.

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.

P. Ettmayer, N. Kraut, M. Gmachl, 2021, Journal of medicinal chemistry.

Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.

S. Carotta, H. Nar, A. Grube, 2023, Journal of medicinal chemistry.

Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage

N. Ratner, E. Dombi, T. Rizvi, 2023, The Journal of Pharmacology and Experimental Therapeutics.

Targeting cancer with small molecule pan-KRAS degraders

M. Koegl, A. Ciulli, W. Farnaby, 2024, bioRxiv.